CA3108066A1 - Interferon-gamma biased agonists - Google Patents

Interferon-gamma biased agonists Download PDF

Info

Publication number
CA3108066A1
CA3108066A1 CA3108066A CA3108066A CA3108066A1 CA 3108066 A1 CA3108066 A1 CA 3108066A1 CA 3108066 A CA3108066 A CA 3108066A CA 3108066 A CA3108066 A CA 3108066A CA 3108066 A1 CA3108066 A1 CA 3108066A1
Authority
CA
Canada
Prior art keywords
amino acid
polypeptide
ifn
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3108066A
Other languages
English (en)
French (fr)
Inventor
Kenan Christopher GARCIA
Juan Luis Mendoza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA3108066A1 publication Critical patent/CA3108066A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3108066A 2018-07-30 2019-07-29 Interferon-gamma biased agonists Pending CA3108066A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712128P 2018-07-30 2018-07-30
US62/712,128 2018-07-30
PCT/US2019/043977 WO2020028275A1 (en) 2018-07-30 2019-07-29 Interferon-gamma biased agonists

Publications (1)

Publication Number Publication Date
CA3108066A1 true CA3108066A1 (en) 2020-02-06

Family

ID=69230882

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3108066A Pending CA3108066A1 (en) 2018-07-30 2019-07-29 Interferon-gamma biased agonists

Country Status (7)

Country Link
US (1) US12410226B2 (https=)
EP (1) EP3830115A4 (https=)
JP (2) JP2021531814A (https=)
AU (1) AU2019313339A1 (https=)
CA (1) CA3108066A1 (https=)
MX (1) MX2021001165A (https=)
WO (1) WO2020028275A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028275A1 (en) 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
WO2022212525A2 (en) 2021-03-30 2022-10-06 City Of Hope Car t cell therapy and ifn gamma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6124599A (ja) * 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
JP2969461B2 (ja) 1988-07-23 1999-11-02 株式会社林原生物化学研究所 ヒトγ−インターフェロンとその製造方法並びに用途
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
DE19535853C2 (de) * 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
SK8292002A3 (en) 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
JP2004522803A (ja) 2001-06-29 2004-07-29 マキシゲン・エイピーエス インターフェロン製剤
AU2003239774A1 (en) * 2002-07-03 2004-01-23 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
EP1877434A2 (en) * 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2809747C (en) 2010-08-30 2018-05-01 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
US10466359B2 (en) * 2013-01-01 2019-11-05 Inuitive Ltd. Method and system for light patterning and imaging
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
WO2020028275A1 (en) 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
EP3883585A4 (en) 2018-11-20 2022-12-14 Innovative Cellular Therapeutics Holdings, Ltd. MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF

Also Published As

Publication number Publication date
JP2021531814A (ja) 2021-11-25
MX2021001165A (es) 2021-07-15
WO2020028275A1 (en) 2020-02-06
US20210309707A1 (en) 2021-10-07
US12410226B2 (en) 2025-09-09
EP3830115A1 (en) 2021-06-09
EP3830115A4 (en) 2022-08-10
JP2024137947A (ja) 2024-10-07
AU2019313339A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
US12060401B2 (en) Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
US20240309083A1 (en) Albumin binding domain fusion proteins
ES2223061T3 (es) Moleculas ctla4 mutantes y uso de las mismas.
CA2986388C (en) Modified interleukin-7 protein and uses thereof
US20210196796A1 (en) Il-2 orthologs and methods of use
EP2498799B1 (en) Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2
US20100021421A1 (en) Fusion proteins and methods for modulation of immune response
KR20170068553A (ko) 인터류킨-15 조성물 및 이의 용도
JP2024137947A (ja) インターフェロン－ガンマバイアス型アゴニスト
JP7742354B2 (ja) Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
JP2007510403A (ja) ケモカイン変異体の治療への使用
KR20230096981A (ko) 변형된 il-2 분자 및 이의 용도
JP2023505590A (ja) インターロイキン２キメラ構築物
US20050069987A1 (en) Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
AU2016323769A1 (en) Compositions comprising pregnancy specific glycoproteins and methods of use thereof
TWI900647B (zh) 識別p53中r273c或y220c突變的t細胞受體
KR20070029636A (ko) 사이토킨 길항제 분자
US20210087252A1 (en) Mutant IDH1 Specific T Cell Receptor
KR20240004453A (ko) 변형된 과립구 집락-자극 인자(g-csf) 및 이에 결합하는 키메라 사이토카인 수용체
EP1859042A2 (en) Novel human, feline, chicken and other animal interferons and uses thereof
HK40126456A (en) Albumin binding domain fusion proteins
HK40076703A (en) Il-2 orthologs and methods of use
EA045513B1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240715

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240729

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240729

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241010

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241010

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250506

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507